NASDAQ:CDMO - Avid Bioservices Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.05 -0.01 (-0.20 %)
(As of 12/19/2018 08:37 AM ET)
Previous Close$5.06
Today's Range$4.96 - $5.1558
52-Week Range$2.24 - $8.44
Volume243,893 shs
Average Volume219,028 shs
Market Capitalization$283.70 million
P/E Ratio-10.10
Dividend YieldN/A
Beta2.6
Avid Bioservices, Inc., a biologics contract development and manufacturing company, focuses on the development and current Good Manufacturing Practices (cGMP) manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, cGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and offers services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission, and support. It also provides various process development services, such as cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.

Receive CDMO News and Ratings via Email

Sign-up to receive the latest news and ratings for CDMO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CDMO
Previous Symbol
CUSIPN/A
Phone714-508-6100

Debt

Debt-to-Equity RatioN/A
Current Ratio2.26
Quick Ratio1.84

Price-To-Earnings

Trailing P/E Ratio-10.10
Forward P/E Ratio-24.05
P/E GrowthN/A

Sales & Book Value

Annual Sales$53.62 million
Price / Sales5.28
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.98 per share
Price / Book5.15

Profitability

EPS (Most Recent Fiscal Year)($0.50)
Net Income$-21,810,000.00
Net Margins-31.20%
Return on Equity-38.67%
Return on Assets-23.25%

Miscellaneous

Employees186
Outstanding Shares56,070,000
Market Cap$283.70 million
OptionableOptionable

Avid Bioservices (NASDAQ:CDMO) Frequently Asked Questions

What is Avid Bioservices' stock symbol?

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

How often does Avid Bioservices pay dividends? What is the dividend yield for Avid Bioservices?

Avid Bioservices announced a dividend on Wednesday, March 7th. Investors of record on Monday, March 19th will be given a dividend of $0.6563 per share on Monday, April 2nd. The ex-dividend date is Friday, March 16th. View Avid Bioservices' Dividend History.

When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work?

Avid Bioservices's stock reverse split before market open on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.

How were Avid Bioservices' earnings last quarter?

Avid Bioservices Inc (NASDAQ:CDMO) released its quarterly earnings results on Monday, December, 10th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.03. The biopharmaceutical company earned $10.18 million during the quarter, compared to the consensus estimate of $10.75 million. Avid Bioservices had a negative net margin of 31.20% and a negative return on equity of 38.67%. View Avid Bioservices' Earnings History.

When is Avid Bioservices' next earnings date?

Avid Bioservices is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Avid Bioservices.

What guidance has Avid Bioservices issued on next quarter's earnings?

Avid Bioservices updated its FY 2019 earnings guidance on Monday, December, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $51-55 million, compared to the consensus revenue estimate of $54.3 million.

What price target have analysts set for CDMO?

5 Wall Street analysts have issued twelve-month price targets for Avid Bioservices' shares. Their predictions range from $4.00 to $11.00. On average, they anticipate Avid Bioservices' stock price to reach $8.3333 in the next twelve months. This suggests a possible upside of 65.0% from the stock's current price. View Analyst Price Targets for Avid Bioservices.

What is the consensus analysts' recommendation for Avid Bioservices?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avid Bioservices.

What are Wall Street analysts saying about Avid Bioservices stock?

Here are some recent quotes from research analysts about Avid Bioservices stock:
  • 1. According to Zacks Investment Research, "Avid Bioservices, Inc. is a dedicated contract development and manufacturing organization focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. It also offer process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. Avid Bioservices Inc., formerly known as Peregrine Pharmaceuticals Inc., is based in TUSTIN, United States. " (12/13/2018)
  • 2. HC Wainwright analysts commented, "Valuation and impediments to achieving price target. We maintain our Buy rating with a price target of $11. Our valuation is based on a discounted EBITDA model, which we believe takes into account both the established and anticipated revenue growth of Avid, which is the cornerstone of the company’s business. We assign a 23x multiple on F2023 EBIDTA discounted back at Avid’s WACC of 13%. We believe that Avid deserves a multiple premium compared to recent CDMO deals in North Avid Bioservices, Inc." (12/11/2018)

Has Avid Bioservices been receiving favorable news coverage?

News articles about CDMO stock have trended neutral recently, according to InfoTrie. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Avid Bioservices earned a daily sentiment score of 0.4 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an effect on the stock's share price in the near future.

Who are some of Avid Bioservices' key competitors?

Who are Avid Bioservices' key executives?

Avid Bioservices' management team includes the folowing people:
  • Dr. Roger J. Lias, Pres, CEO & Director (Age 58)
  • Mr. Mark R. Ziebell, VP, Gen. Counsel & Corp. Sec. (Age 54)
  • Mr. Daniel R. Hart, Chief Financial Officer (Age 45)
  • Ms. Tracy L. Kinjerski, VP of Bus. Operations
  • Mr. Stephen Michael Hedberg, Sr. Director of Fin. & SEC Reporting and Principal Financial & Accounting Officer (Age 43)

Who are Avid Bioservices' major shareholders?

Avid Bioservices' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.39%), Vanguard Group Inc. (4.16%), Vanguard Group Inc (4.16%), EAM Investors LLC (0.53%), EAM Global Investors LLC (0.37%) and TIAA CREF Investment Management LLC (0.32%). Company insiders that own Avid Bioservices stock include Joel Mccomb and Mark R Bamforth. View Institutional Ownership Trends for Avid Bioservices.

Which institutional investors are selling Avid Bioservices stock?

CDMO stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN and JPMorgan Chase & Co.. View Insider Buying and Selling for Avid Bioservices.

Which institutional investors are buying Avid Bioservices stock?

CDMO stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., EAM Investors LLC, EAM Global Investors LLC, SG Americas Securities LLC, Vanguard Group Inc, Vanguard Group Inc., Granite Investment Partners LLC and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Avid Bioservices.

How do I buy shares of Avid Bioservices?

Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Avid Bioservices' stock price today?

One share of CDMO stock can currently be purchased for approximately $5.05.

How big of a company is Avid Bioservices?

Avid Bioservices has a market capitalization of $283.70 million and generates $53.62 million in revenue each year. The biopharmaceutical company earns $-21,810,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Avid Bioservices employs 186 workers across the globe.

What is Avid Bioservices' official website?

The official website for Avid Bioservices is http://www.avidbio.com.

How can I contact Avid Bioservices?

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at 714-508-6100 or via email at [email protected]


MarketBeat Community Rating for Avid Bioservices (NASDAQ CDMO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  236 (Vote Outperform)
Underperform Votes:  203 (Vote Underperform)
Total Votes:  439
MarketBeat's community ratings are surveys of what our community members think about Avid Bioservices and other stocks. Vote "Outperform" if you believe CDMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDMO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/19/2018 by MarketBeat.com Staff

Featured Article: Catch-Up Contributions

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel